Revenue up at MannKind, but losses mount
Westlake Village-based biotech company MannKind saw a slight bump in revenue in the first quarter thanks to its product Afrezza, but net losses continued to climb. MannKind released its earnings after the markets closed on May 12. It ended the day down 8.6% and regained 0.25% on May 13, to close at $4.03. MannKind, which Read More →
Read More →MannKind stock dips on report of 2020 losses, but company touts fourth quarter comeback
MannKind Corp. struggled during 2020, but impressive financial results from its final quarter could be a sign of good things to come for the Westlake Village biotech company. MannKind, which develops drugs and treatments for those suffering from diabetes and pulmonary arterial hypertension, reported a net loss of $57.2 million in fiscal year 2020, up Read More →
Read More →
MannKind beats earnings estimates
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Tri-county stocks mixed as national indices drop slightly
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Most tri-county stocks end up for the day
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Tri-county biotech firms tackle COVID-19 pandemic
Life sciences companies in the Tri-Counties are stepping up with treatments for COVID-19, led by leaders in inhalable drug technologies. Westlake Village-based MannKind said it expects $4.9 million in forgivable loan relief as part of the CARES Act, passed in March, as it explores four potential anti-infective and antiviral therapies. Separately, aerosolized drug delivery company Read More →
Read More →MannKind getting $5M loan to avoid layoffs and tackle COVID-19
Westlake Village-based MannKind said it expects $4.9 million in federal forgivable loan relief, among other financial measures that will help it avoid furloughs and layoffs as it pursues potential therapies for the COVID-19 pandemic. The company is currently exploring four potential anti-infective and antiviral therapies, said CEO Michael Castagna. “These are high risk areas and Read More →
Read More →
Sponsored content:
2015-2016 Giving Guide
